Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fate Therapeutics (FATE) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Fate Therapeutics (FATE) over the last 14 years, with Q3 2025 value amounting to $2.5 million.

  • Fate Therapeutics' Non Operating Income fell 4711.64% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.6 million, marking a year-over-year increase of 144.24%. This contributed to the annual value of $24.0 million for FY2024, which is 1882.5% down from last year.
  • Fate Therapeutics' Non Operating Income amounted to $2.5 million in Q3 2025, which was down 4711.64% from $2.9 million recorded in Q2 2025.
  • Over the past 5 years, Fate Therapeutics' Non Operating Income peaked at $11.3 million during Q3 2021, and registered a low of -$8.4 million during Q2 2021.
  • For the 5-year period, Fate Therapeutics' Non Operating Income averaged around $5.0 million, with its median value being $4.7 million (2024).
  • Its Non Operating Income has fluctuated over the past 5 years, first tumbled by 141559.06% in 2021, then surged by 95860.71% in 2022.
  • Quarter analysis of 5 years shows Fate Therapeutics' Non Operating Income stood at $761000.0 in 2021, then surged by 958.61% to $8.1 million in 2022, then crashed by 50.93% to $4.0 million in 2023, then soared by 142.73% to $9.6 million in 2024, then plummeted by 74.1% to $2.5 million in 2025.
  • Its Non Operating Income was $2.5 million in Q3 2025, compared to $2.9 million in Q2 2025 and $3.7 million in Q1 2025.